FDA approves Roche immunotherapy cocktail in liver cancer
Swiss drugmaker Roche said on Friday that the U.S. Food and Drug Administration (FDA) approved its immunotherapy Tecentriq in combination with its drug Avastin for the most common kind of liver cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health | Immunotherapy | Liver | Switzerland Health | Urology & Nephrology